Oramed's (ORMP) ORMD-0801 Likely Better Insulin-Delivery Option vs. Afrezza; Aegis Afirms' Buy' Rating (MNKD)
Tweet Send to a Friend
Aegis Capital affirms Oramed Pharma (Nasdaq; ORMP) at Buy with a price target of $32 following recent news that MannKind's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
